Hantavirus infections and their prevention

Microbes and Infection

Volumn 3, Issue 13, 2001, Pages 1129-1144

  Krüger, Detlev H ^a   Ulrich, Rainer ^a   Lundkvist, Åke ^b,c  

^a HUMBOLDT UNIVERSITY   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Bunyaviridae; Hantavirus; Rodent borne viruses; Vaccine development; Virus diagnostics

Indexed keywords

ANTIVIRUS AGENT; BETA INTERFERON; CYTOKINE; DNA VACCINE; EPITOPE; GUANINE NUCLEOTIDE BINDING PROTEIN; HANTAVAX; INACTIVATED VACCINE; LIVE VACCINE; MONOCLONAL ANTIBODY; RIBAVIRIN; VACCINIA VACCINE; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

CLINICAL FEATURE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG SAFETY; GENETIC SUSCEPTIBILITY; HANTAVIRUS; HANTAVIRUS PULMONARY SYNDROME; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEROTYPE; VIRUS CELL INTERACTION; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS TRANSMISSION;

BUNYAVIRIDAE; HANTAVIRUS; ORTHOBUNYAVIRUS; RODENTIA;

EID: 0034764441     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(01)01474-5     Document Type: Review

References (165)

1. Emerging viruses: The evolution of viruses and viral diseases
2. Isolation of the etiologic agent of Korean hemorrhagic fever
3. Hemorrhagic fever with renal syndrome: Global epidemiology and ecology of hantavirus infections
4. Nephropathia epidemica: Detection of antigen in bank voles and serologic diagnosis of human infection
5. Beobachtungen zur pathogenese und aetiologie von nierenentzündungen im feldzug im osten winter 1941/42
6. Bericht über ein neues schlammfieberähnliches krankheitsbild bei deutschen truppen in lappland
7. Virus hemorrhagic fevers
8. Haemorrhagic fever with renal syndrome: Memorandum from a WHO meeting
9. Hemorrhagic fever with renal syndrome
10. Antigenic and genetic properties of viruses linked to hemorrhagic fever with renal syndrome
11. Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness
12. Hantavirus infections in Europe
13. Hantaviruses: Genome structure, expression and evolution
14. Isolation and characterization of a hantavirus from Lemmus sibiricus: Evidence for host switch during hantavirus evolution
15. Virus evolution and genetic diversity of hantaviruses and their rodent hosts
16. Persistent hantavirus infections: Characteristics and mechanisms
17. Genetic variation of wild Puumala viruses within the serotype, local rodent populations and individual animal
18. Quasispecies in wild-type Tula hantavirus populations
19. Temporal and spatial analysis of Sin Nombre virus quasispecies in naturally infected rodents
20. Recombination in Tula hantavirus evolution: Analysis of genetic lineages from Slovakia
21. Naturally occurring Sin Nombre virus genetic reassortants
22. Complete nucleotide sequences of the M and S segments of two hantavirus isolates from California: Evidence for reassortment in nature among viruses related to hantavirus pulmonary syndrome
23. Genetic reassortment among viruses causing hantavirus pulmonary syndrome
24. Genetic analysis of the diversity and origin of hantaviruses in Peromyscus leucopus mice in North America
25. Hantavirus pulmonary syndrome outbreak in Argentina: Molecular evidence for person-to-person transmission of Andes virus
26. Dobrava hantavirus causes hemorrhagic fever with renal syndrome (HFRS) in central Europe and is carried by two different Apodemus mice species
27. Clinical characterization of Dobrava hantavirus infections in Germany
28. Puumala and Dobrava hantaviruses causing hemorrhagic fever with renal syndrome in Estonia
29. Dobrava hantavirus in Estonia: Does the virus exist throughout Europe?
30. Isolation and characterisation of Dobrava hantavirus carried by the striped field mouse (Apodemus agrarius) in Estonia
31. Hemorrhagic fever with renal syndrome in the Dolenjska region of Slovenia - A 10-year survey
32. Nephropathia epidemica in Finland: A clinical, histological and epidemiological study
33. Nephropathia epidemica (hemorrhagic fever with renal syndrome) in Scandinavia
34. Hantavirus pulmonary syndrome: A clinical description of 17 patients with a newly recognized disease
35. Pathogenesis of Puumala and other hantavirus infections
36. Hantavirus infection
37. Spectrum of hantavirus infection: Hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome
38. Mechanisms of disease in hantavirus infection: Pathophysiology of hemorrhagic fever with renal syndrome
39. Hantavirus pulmonary syndrome: Pathogenesis of an emerging infectious disease
40. Hantavirus pulmonary syndrome in the United States: A pathological description of a disease caused by a new agent
41. Hantavirus pulmonary syndrome: CD8+ and CD4+ cytotoxic T lymphocytes to epitopes on Sin Nombre virus nucleocapsid protein isolated during acute illness
42. Human memory cytotoxic T-lymphocyte (CTL) responses to Hantaan virus infection: Identification of virus-specific and cross-reactive CD8+ CTL epitopes on nucleocapsid protein
43. Elevated plasma levels of tumor necrosis factor (TNF)-alpha, soluble TNF receptors, interleukin (IL)-6, and IL-10 in patients with hemorrhagic fever with renal syndrome
44. The participation of histamine and serotonin in the genesis of acute kidney failure in patients with hemorrhagic fever with renal syndrome (in Russian)
45. Increased production of nitric oxide in patients infected with the European variant of hantavirus
46. Association of serine in position 1124 of Hantaan virus glycoprotein with virulence in mice
47. Comparison of virulence between two strains of Rattus serotype hemorrhagic fever with renal syndrome (HFRS) virus in newborn rats
48. Cell culture adaptation of Puumala hantavirus changes the infectivity for its natural reservoir, Clethrionomys glareolus, and leads to accumulation of mutants with altered genomic RNA S segment
49. Experimental hantavirus infection in nonhuman primates
50. A macaque model for hantavirus infection
51. Genetic susceptibility to severe course of nephropathia epidemica caused by Puumala hantavirus
52. Puumala hantavirus genome in patients with nephropathia epidemica: Correlation of PCR positivity with HLA haplotype and link to viral sequences in local rodents
53. Association of HLA B27 with benign clinical course of nephropathia epidemica caused by Puumala hantavirus
54. High-producer allele of tumour necrosis factor-alpha is part of the susceptibility MHC haplotype in severe Puumala virus-induced nephropathia epidemica
55. Distribution and genetic heterogeneity of Puumala virus in Sweden
56. Spatial and temporal dynamics of hantavirus infection in red bank vole (Clethrionomys glareolus) populations in Belgium
57. Detection and subsequent sequencing of Puumala virus from human specimens by polymerase chain reaction
58. Analysis of Puumala hantavirus genome in patients with nephropathia epidemica and rodent carriers from the sites of infection
59. Retrospective serological and genetic study of the distribution of hantaviruses in Greece
60. Korean hemorrhagic fever with renal syndrome. I. Demonstration of causative antigen and antibodies
61. Korean hemorrhagic fever: Propagation of the etiologic agent in a cell line of human origin
62. Hemagglutination inhibiting antibody in hemorrhagic fever with renal syndrome
63. Detection of hemagglutination-inhibiting antibodies in patients with nephropathia epidemica and Korean hemorrhagic fever by using Puumala virus cell culture antigen
64. Determination by immune adherence HA of the antigenic relationship between Rattus- and Apodemus-borne viruses causing hemorrhagic fever with renal syndrome
65. An immune adherence assay for discrimination between etiologic agents of hemorrhagic fever with renal syndrome
66. A simple method of preparing a complement-fixing antigen from the virus of hemorrhagic fever with renal syndrome (western type)
67. Rapid serodiagnosis of hantavirus infections using high density particle agglutination
68. Rapid diagnosis of hantavirus disease with an IgG-avidity assay
69. Use of recombinant nucleocapsid proteins of the Hantaan and nephropathia epidemica serotypes of hantaviruses as immunodiagnostic agents
70. The humoral response to Puumala virus infection (nephropathia epidemica) investigated by viral protein specific immunoassays
71. Antigenic properties and diagnostic potential of Puumala virus nucleocapsid protein expressed in insect cells
72. Evaluation of serological methods for diagnosis of Puumala hantavirus infection (nephropathia epidemica)
73. Dobrava virus infection: Serological diagnosis and cross-reactions to other hantaviruses
74. Immunoblot analysis of the serological response in Hantavirus infections
75. A retrospective analysis of sera collected by the Hemorrhagic Fever Commission during the Korean conflict
76. Serum antibodies to structural proteins of Hantavirus arise at different times after infection
77. Mapping of B-cell determinants in the nucleocapsid protein of Puumala virus; definition of epitopes specific for acute IgG recognition in humans
78. Puumala and Dobrava viruses cause hemorrhagic fever with renal syndrome in Bosnia-Herzegovina: Evidence of highly cross-neutralizing antibody responses in early patient sera
79. Evaluation of Puumala virus IgG and IgM enzyme immunoassays based on recombinant baculovirus expressed nucleocapsid protein for early nephropathia epidemica diagnosis
80. A novel μ-capture EIA based on recombinant proteins for sensitive and specific diagnosis of hemorrhagic fever with renal syndrome
81. Seroprevalence of hantavirus antibodies in Germany as determined by a new recombinant enzyme immunoassay
82. Antigenic properties and diagnostic potential of recombinant Dobrava virus nucleocapsid protein
83. A major antigenic domain for the human humoral response to Puumala virus nucleocapsid protein is located at the amino-terminus
84. A major antigenic domain of Hantaviruses is located on the aminoproximal site of the viral nucleocapsid protein
85. Characterization of Puumala virus nucleocapsid protein: Identification of B-cell epitopes and domains involved in protective immunity
86. Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants
87. Diagnostic potential of Puumala virus nucleocapsid protein expressed in Drosophila melanogaster cells
88. The clinical usefulness of a Puumala virus recombinant nucleocapsid protein based enzyme-linked immunosorbent assay in the diagnosis of nephropathia epidemica as compared with an immunofluorescence assay
89. Antigenic characterization of Hantaan and Seoul virus nucleocapsid proteins expressed by recombinant baculovirus: Application of a truncated protein, lacking an antigenic region common to the two viruses, as a serotyping antigen
90. Hantavirus infections in The Netherlands: Epidemiology and disease
91. Simultaneous occurrence of Dobrava, Puumala, and Tula hantaviruses in Slovakia
92. Prevalence of antibodies specific to Puumala virus among farmers in Sweden
93. Puumala virus infections in Finland: Increased occupational risk for farmers
94. Seroprevalence of antibodies to hantaviruses and leptospires in selected Italian population groups
95. Hantavirus antibodies in European mammalogists
96. Hantavirus infections among mammalogists studied by focus reduction neutralization test
97. A study of nephropathia epidemica among military personnel in Sweden
98. A case-controlled study of hantavirus pulmonary syndrome during an outbreak in the southwestern United States
99. A case-controlled study after a hantavirus infection outbreak in the South of Belgium: Who is at risk?
100. Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies
101. Antibody-dependent enhancement of hantavirus infection in macrophage cell lines
102. Characterization of Hantaan virus envelope glycoprotein antigenic determinants defined by monoclonal antibodies
103. Monoclonal antibodies to three strains of hantaviruses: Hantaan, R22, and Puumala
104. Bank vole monoclonal antibodies against Puumala virus envelope glycoproteins: Identification of epitopes involved in neutralization
105. Neutralizing human monoclonal antibodies against Puumala virus, causative agent of nephropathia epidemica: A novel method using antigen-coated magnetic beads for specific B cell isolation
106. Serological relationships among viruses in the Hantavirus genus, family Bunyaviridae
107. Anti-idiotype antibodies against Puumala virus glycoprotein-specific monoclonal antibodies inhibit virus infection in cell cultures
108. Intramuscular inoculation of Sin Nombre hantavirus cDNAs induces cellular and humoral immune response in BALBc mice
109. A neutralizing recombinant human antibody Fab fragment against Puumala hantavirus
110. Epitope mapping studies with neutralizing and non-neutralizing antibodies to the G1 and G2 envelope glycoproteins of Hantaan virus
111. Single amino acid substitutions in Puumala virus envelope glycoproteins G1 and G2 eliminate important neutralization epitopes
112. Phage-displayed peptide targeting on the Puumala hantavirus neutralization site
113. Phage-displayed peptides mimicking the discontinous neutralization sites of Puumala hantavirus envelope glycoproteins
114. Immune spleen cell-mediated protection against fatal Hantaan virus infection in infant mice
115. Role of T lymphocyte subsets in protection and recovery from Hantaan virus infection in mice
116. Cell-mediated immunity to virus causing haemorrhagic fever with renal syndrome: Generation of cytotoxic T lymphocytes
117. Protective immunity of Hantaan virus nucleocapsid and envelope protein studied using baculovirus-expressed proteins
118. T-helper and humoral responses to Puumala hantavirus nucleocapsid protein: Identification of T-helper epitopes in a mouse model
119. Characterization of the nucleocapsid protein of Hantaan virus strain 76-118 using monoclonal antibodies
120. Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model
121. Antigenic variation of European haemorrhagic fever with renal syndrome virus strains characterized using bank vole monoclonal antibodies
122. Puumala (PUU) hantavirus strain differences and insertion positions in the hepatitis B virus core antigen influence B-cell immunogenicity and protective potential of core-derived particles
123. Vaccines against hemorrhagic fever with renal syndrome
124. Inactivated cell-culture Hantavirus vaccine developed in China
125. A vaccinia virus-vectored Hantaan virus vaccine protects hamsters from challenge with Hantaan and Seoul viruses but not Puumala virus
126. Immunity to hantavirus challenge in Meriones unguiculatus induced by vaccinia-vectored viral proteins
127. Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon and packaged Sindbis replicon vectors expressing hantavirus structural genes in hamsters
128. Immune responses to inactivated vaccine in people naturally infected with hantaviruses
129. Cross-reactive immunity among different serotypes of virus causing haemorrhagic fever with renal syndrome
130. Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNAs
131. Negative-strand RNA viruses: Genetic engineering and applications
132. Prospects for vaccines to control viruses in the family Bunyaviridae
133. Antibody responses in humans to an inactivated hantavirus vaccine (Hantavax R)
134. Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine
135. Recombinant DNA vaccines for hantaviruses
136. Preparation of candidate vaccinia-vectored vaccines for haemorrhagic fever with renal syndrome
137. Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine
138. Core particles of hepatitis B virus as carrier for foreign epitopes
139. Nucleocapsid- and virus-like particles assemble in cells infected with recombinant baculoviruses or vaccinia viruses expressing the M and S segments of Hantaan virus
140. HBV core particles allow the insertion and surface exposure of the entire potentially protective region of Puumala hantavirus nucleocapsid protein
141. DNA vaccines for viral diseases
142. DNA vaccination with hantavirus M segments elicits neutralizing antibodies and protects against Seoul virus infection
143. DNA vaccination of mice with a plasmid encoding Puumala hantavirus nucleocapsid protein mimicks the B-cell response induced by virus infection
144. Molecular approaches for the treatment of hemorrhagic fever virus infections
145. Broad-spectrum antiviral activity of 2-β-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent
146. Ribavirin therapy for Hantaan virus infection in suckling mice
147. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome
148. Intravenous ribavirin for hantavirus pulmonary syndrome: Safety and tolerance during 1 year of open-label experience, Ribavirin Study Group
149. Effects of human and murine interferons against hemorrhagic fever with renal syndrome (HFRS) virus (Hantaan virus)
150. Effect of interferon-α and cell differentiation on Puumala virus infection in human monocyte/macrophages
151. Inhibition of Puumala and Tula hantaviruses in Vero cells by MxA protein
152. Inhibition of bunyaviruses, phleboviruses, and hantaviruses by human MxA protein
153. New World hantaviruses
154. Genetic analysis of wild-type Dobrava hantavirus in Slovenia: Co-existence of two distinct genetic lineages within the same natural focus
155. Field trial of an inactivated vaccine against hemorrhagic fever with renal syndrome in humans
156. The investigation on the use of the inactivated epidemic hemorrhagic fever tissue culture vaccine in humans
157. Comparative studies of the immunogenicity of different types of HFRS inactivated vaccines made in China
158. A field study on the use of inactivated vaccine against epidemic hemorrhagic fever
159. Studies on the purified inactivated epidemic hemorrhagic fever (EHF) vaccine. IX: Clinical trial of type I EHF vaccine in volunteers
160. Epidemiological study on the preventive effect of the inactivated vaccine against HFRS in D.P.R. Korea
161. Studies on the purified inactivated epidemic hemorrhagic fever (EHF) vaccine. X: Clinical trial of type II EHF vaccine
162. Preliminary human trial of inactivated golden hamster kidney cell (GHKC) vaccine against haemorrhagic fever with renal syndrome (HFRS)
163. Development of inactivated vaccine against virus causing haemorrhagic fever with renal syndrome